Lista de obras -

A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors

artículo científico publicado en 2005

A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy

scientific article published on 01 December 1996

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

artículo científico publicado en 2007

AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group

artículo científico publicado en 1996

Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

artículo científico

Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior

scientific article published on 01 February 1999

Anticoagulation and hemostasis in cardiac surgical patients

scientific article published on 01 July 1994

Antithrombotic Agents and Thromboembolic Disease ⬇️

artículo científico publicado el 6 de noviembre de 1997

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

artículo científico publicado en 2016

Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation

artículo científico publicado en 1993

BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression

artículo científico publicado en 2020

Biochemical studies on the H-2K antigens of the MHC mutant bml.

artículo científico publicado en 1981

Biochemical studies on the H-2K antigens of the MHC mutants bm3 and bm11.

artículo científico publicado en 1980

Biochemical studies on the H-2K mutant B6.C-H-2bm10

artículo científico publicado en 1983

Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients ⬇️

artículo científico publicado el 1 de septiembre de 2010

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

artículo científico publicado en 2008

Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors

artículo científico publicado en 2009

Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells ⬇️

artículo científico publicado el 1 de septiembre de 1992

Cancer and venous thromboembolism

artículo científico publicado en 1996

Central venous access devices in haemophilia

artículo científico publicado en 2004

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.

artículo científico publicado en 2004

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

artículo científico publicado en 2010

Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells

artículo científico publicado en 1987

Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement.

artículo científico publicado en 2004

Consensus recommendations for use of central venous access devices in haemophilia

artículo científico publicado en 2004

Continuous infusion of recombinant factor VIIa: continue or not?

artículo científico publicado en 2001

Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries

scientific article published on 27 April 2009

Development of a plasma- and albumin-free recombinant von Willebrand factor.

artículo científico publicado en 2009

Development of novel treatment options for patients with haemophilia.

artículo científico

Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States

scientific article published on 14 December 2020

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.

artículo científico publicado en 2015

Emerging clinical concerns in the ageing haemophilia patient

artículo científico publicado en 2009

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A

artículo científico publicado en 2012

Expression and activation of protein kinase C isoforms in a human megakaryocytic cell line.

artículo científico publicado en 1996

FEIBA safety profile in multiple modes of clinical and home-therapy application

artículo científico publicado en 2004

FVIII administration in surgery ⬇️

artículo científico publicado el 20 de junio de 2011

Factor IX inhibitors and anaphylaxis in haemophilia B.

artículo científico publicado en 1996

Factor IX inhibitors and anaphylaxis in hemophilia B

artículo científico publicado en 1997

Factor IX inhibitors and anaphylaxis in hemophilia B.

artículo científico publicado en 1997

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

artículo científico publicado en 2009

Further structural analysis of the murine H-Kkb glycoprotein using radiochemical methodology ⬇️

artículo científico publicado el 1 de enero de 1979

Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods

artículo científico publicado en 2005

Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States

artículo científico publicado en 2012

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-

artículo científico publicado en 2004

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

artículo científico publicado en 2015

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

artículo científico publicado en 1998

IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis

scientific article published on 01 June 1989

IgE-mediated allergy and desensitization to factor IX in hemophilia B.

artículo científico publicado en 1998

Immortalization of human endothelial cells by murine sarcoma viruses, without morphologic transformation.

artículo científico publicado en 1988

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.

artículo científico publicado en 2000

Individualizing prophylaxis in hemophilia: a review

artículo científico publicado en 2015

Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.

artículo científico publicado en 2000

Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions

scientific article published on 01 April 1997

Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study

artículo científico publicado en 2004

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

article

Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina ⬇️

artículo científico publicado el 7 de julio de 2011

Localization of the papain cleavage site of H-2 glycoproteins ⬇️

artículo científico publicado el 1 de marzo de 1976

Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America

artículo científico publicado en 2001

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.

artículo científico publicado en 1998

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors

artículo científico publicado en 2011

Molecular studies of von Willebrand disease: reduced von Willebrand factor biosynthesis, storage, and release in endothelial cells derived from patients with type I von Willebrand disease

scientific article published on 01 April 1990

Nephrotic syndrome as a complication of immune tolerance in hemophilia B.

artículo científico publicado en 1997

Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts

artículo científico publicado en 2019

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

artículo científico publicado en 2015

Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells

scientific article published on 01 December 1995

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

artículo científico publicado en 2002

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

artículo científico publicado en 2013

Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

artículo científico publicado en 2008

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight ⬇️

artículo científico publicado el 31 de octubre de 2011

Porcine factor VIII: pharmacoeconomics of inhibitor therapy

artículo científico publicado en 2002

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

artículo científico publicado en 2010

Primary structural: analysis of the transplantation antigens of the murine H-2 major histocompatibility complex

artículo científico publicado en 1981

Primary structure of murine H-2Kb and beta 2-microglobulin

artículo científico publicado el 1 de diciembre de 1981

Primary structure of murine major histocompatibility alloantigens: amino acid sequence of the cyanogen bromide fragment Ia (positions 139-228) from the H-2Kb molecule

artículo científico publicado en 1980

Primary structure of murine major histocompatibility complex alloantigens: Amino acid sequence studies of the cyanogen bromide fragments of the H-2K b glycoprotein ⬇️

artículo científico publicado el 1 de julio de 1978

Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence of the amino-terminal one hundred and seventy-three residues of the H-2Kb glycoprotein

artículo científico publicado en 1980

Primary structure of murine major histocompatibility complex alloantigens: completion of the sequence of the amino-terminal 284 residues of H-2Kb

scientific article published on 01 December 1980

Primary structure of murine major histocompatibility complex alloantigens: isolation, biochemical characterization, and preliminary alignment of CNBr fragments from the H-2Ib glycoprotein ⬇️

artículo científico publicado el 1 de junio de 1978

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy

artículo científico publicado en 2016

Prolonged peak elevations in cytoplasmic free calcium ions, derived from intracellular stores, correlate with the extent of thrombin-stimulated exocytosis in single human umbilical vein endothelial cells

artículo científico publicado en 1994

Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden

scientific article published on 01 June 1996

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.

artículo científico publicado en 2013

Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on‐demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study ⬇️

artículo científico publicado el 13 de julio de 2011

Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura

artículo científico publicado en 2017

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura

artículo científico publicado en 2017

Recombinant factor VIII: are we really getting more for less?

artículo científico publicado en 1997

Regulated Secretion in Vascular Endothelium ⬇️

artículo científico publicado el 1 de enero de 1991

Regulated secretion in endothelial cells: biology and clinical implications

artículo científico publicado en 2001

Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males

artículo científico publicado en 2001

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature

artículo científico publicado en 2008

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study

artículo científico publicado en 2020

Severe haemophilia A in a female resulting from two de novo factor VIII mutations.

artículo científico publicado en 1995

Structural Differences between Parent and Variant H-2K Glycoproteins from Mouse Strains Carrying H-2 Gene Mutations ⬇️

artículo científico publicado el 1 de enero de 1977

Structure of pre-pro-von Willebrand factor and its expression in heterologous cells

artículo científico publicado en 1986

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).

artículo científico publicado en 2004

Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

artículo científico publicado en 2003

Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients

artículo científico publicado en 2008

Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells

artículo científico publicado en 1999

The 1st International Standard for von Willebrand Factor concentrate: more to come?

scientific article published on 01 September 2002

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

artículo científico publicado en 2009

The burden of bleeding in haemophilia: is one bleed too many?

artículo científico publicado en 2014

The economic impact of factor VIII inhibitors in patients with haemophilia

artículo científico publicado en 2004

The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding

artículo científico publicado en 1996

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

artículo científico publicado en 2011

The role of previously untreated patient studies in understanding the development of FVIII inhibitors

artículo científico

The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease

artículo científico publicado en 2017

The structural-genetic relationships of the H-2K and H-2D products of the mouse major histocompatibility complex

artículo científico publicado en 1978

Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF ⬇️

artículo científico publicado el 1 de diciembre de 1997

Thrombin and histamine rapidly stimulate the phosphorylation of the myristoylated alanine-rich C-kinase substrate in human umbilical vein endothelial cells: evidence for distinct patterns of protein kinase activation

artículo científico publicado en 1992

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

artículo científico publicado en 2002

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

artículo científico publicado en 2011

Tumor necrosis factor induction of endothelial cell surface antigens is independent of protein kinase C activation or inactivation. Studies with phorbol myristate acetate and staurosporine ⬇️

artículo científico publicado el 1 de mayo de 1991

Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.

artículo científico publicado en 2017

Use of ristocetin cofactor activity in the management of von Willebrand disease

artículo científico publicado en 2001

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

artículo científico publicado en 1998

Von Willebrand's disease.

artículo científico publicado en 1997

Lista de obras de

A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors

A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group

Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior

Anticoagulation and hemostasis in cardiac surgical patients

Antithrombotic Agents and Thromboembolic Disease ⬇️

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation

BAX 335 hemophilia B gene therapy clinical trial results - potential impact of CpG sequences on gene expression

Biochemical studies on the H-2K antigens of the MHC mutant bml.

Biochemical studies on the H-2K antigens of the MHC mutants bm3 and bm11.

Biochemical studies on the H-2K mutant B6.C-H-2bm10

Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients ⬇️

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors

Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells ⬇️

Cancer and venous thromboembolism

Central venous access devices in haemophilia

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells

Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement.

Consensus recommendations for use of central venous access devices in haemophilia

Continuous infusion of recombinant factor VIIa: continue or not?

Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries

Development of a plasma- and albumin-free recombinant von Willebrand factor.

Development of novel treatment options for patients with haemophilia.

Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.

Emerging clinical concerns in the ageing haemophilia patient

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A

Expression and activation of protein kinase C isoforms in a human megakaryocytic cell line.

FEIBA safety profile in multiple modes of clinical and home-therapy application

FVIII administration in surgery ⬇️

Factor IX inhibitors and anaphylaxis in haemophilia B.

Factor IX inhibitors and anaphylaxis in hemophilia B

Factor IX inhibitors and anaphylaxis in hemophilia B.

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Further structural analysis of the murine H-Kkb glycoprotein using radiochemical methodology ⬇️

Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods

Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis

IgE-mediated allergy and desensitization to factor IX in hemophilia B.

Immortalization of human endothelial cells by murine sarcoma viruses, without morphologic transformation.

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper.

Individualizing prophylaxis in hemophilia: a review

Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.

Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions

Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina ⬇️

Localization of the papain cleavage site of H-2 glycoproteins ⬇️

Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors

Molecular studies of von Willebrand disease: reduced von Willebrand factor biosynthesis, storage, and release in endothelial cells derived from patients with type I von Willebrand disease

Nephrotic syndrome as a complication of immune tolerance in hemophilia B.

Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight ⬇️

Porcine factor VIII: pharmacoeconomics of inhibitor therapy

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Primary structural: analysis of the transplantation antigens of the murine H-2 major histocompatibility complex

Primary structure of murine H-2Kb and beta 2-microglobulin

Primary structure of murine major histocompatibility alloantigens: amino acid sequence of the cyanogen bromide fragment Ia (positions 139-228) from the H-2Kb molecule

Primary structure of murine major histocompatibility complex alloantigens: Amino acid sequence studies of the cyanogen bromide fragments of the H-2K b glycoprotein ⬇️

Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence of the amino-terminal one hundred and seventy-three residues of the H-2Kb glycoprotein

Primary structure of murine major histocompatibility complex alloantigens: completion of the sequence of the amino-terminal 284 residues of H-2Kb

Primary structure of murine major histocompatibility complex alloantigens: isolation, biochemical characterization, and preliminary alignment of CNBr fragments from the H-2Ib glycoprotein ⬇️

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy